Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia

Phase III Sickle Cell Data Due Before Year’s End

 
• By Mandy Jackson
  
Analysts expect Pyrukynd to receive FDA approval to treat thalassemia despite the action date delay (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip